Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Operating Leases (2019 - 2025)

Serina Therapeutics' Operating Leases history spans 4 years, with the latest figure at $311000.0 for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $311000.0; the TTM value through Sep 2025 reached $311000.0, changed N/A, while the annual FY2024 figure was $268000.0, 60.3% down from the prior year.
  • Operating Leases for Q3 2025 was $311000.0 at Serina Therapeutics, down from $362000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $675000.0 in Q4 2023 and bottomed at $268000.0 in Q4 2024.
  • The 3-year median for Operating Leases is $336500.0 (2025), against an average of $404000.0.
  • The largest YoY upside for Operating Leases was 60.3% in 2024 against a maximum downside of 60.3% in 2024.
  • A 3-year view of Operating Leases shows it stood at $675000.0 in 2023, then crashed by 60.3% to $268000.0 in 2024, then rose by 16.04% to $311000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Operating Leases are $311000.0 (Q3 2025), $362000.0 (Q2 2025), and $268000.0 (Q4 2024).